Markets Stocks Economy Crypto Earnings Banking Energy
Home Stocks Feature
Stocks · Exclusive

UBS raises BXP price target to $70 on leasing strength into 2027

UBS raises BXP price target to $70 on leasing strength into 2027
Stocks · 2026
Photo · Marcus Devlin for Daily Digest Invest
By Marcus Devlin Equities Correspondent Aug 25, 2026 4 min read

UBS analysts have raised their price target on Boston Properties (BXP) to $70, signaling confidence that the office real estate investment trust (REIT) has a leasing pipeline strong enough to drive earnings growth into 2027. The move comes after BXP increased its 2026 funds from operations (FFO) guidance to a range of $6.99 to $7.05 per share, even though the company is accelerating asset sales that will weigh on this year's results.

What is FFO and why does it matter?

For REITs like BXP, funds from operations is a key profitability metric. Unlike standard earnings, FFO adds back depreciation and amortization, which are typically large for real estate companies because properties lose value on paper over time even when their actual market value is rising. Investors watch FFO closely because it gives a clearer picture of a REIT's cash-generating ability from its properties.

BXP's revised guidance for 2026 suggests the company expects its core leasing business to remain healthy. The higher end of the range, $7.05 per share, would represent a solid level of cash generation, assuming the company executes on its leasing pipeline.

Why asset sales are a double-edged sword

The company is also selling properties faster than previously planned. While these sales bring in cash and can reduce debt, they also shrink the portfolio, which typically reduces rental income and can drag on near-term FFO. That explains why UBS notes that faster asset sales will weigh on results this year, even as the leasing pipeline points to stronger performance further out.

For investors, this is a classic trade-off: selling assets today can boost balance-sheet flexibility but may temporarily depress earnings. The fact that BXP is still raising its 2026 FFO guidance suggests management believes the leasing wins will more than offset the impact of the sales.

What it means for investors

UBS's $70 price target implies meaningful upside from where BXP shares have traded recently, though the stock's exact level is not specified in the brief. The analyst action is a vote of confidence in BXP's ability to navigate a challenging office market, where remote work and high interest rates have pressured valuations across the sector.

For everyday investors, the key takeaway is that BXP is positioning itself for a stronger 2026 and 2027, even if this year's numbers take a hit from asset sales. The raised guidance and the analyst's price target suggest that the market may be undervaluing the company's long-term leasing prospects.

However, it's important to remember that analyst price targets are opinions, not guarantees. Office REITs remain sensitive to interest rates and the broader economy. If borrowing costs stay high or demand for office space weakens further, BXP's leasing pipeline could face headwinds.

Context in the broader market

BXP's situation is part of a larger story in commercial real estate. Many office landlords have been struggling with high vacancy rates and refinancing challenges. But companies with high-quality, well-located properties—like BXP's portfolio in major U.S. cities—have been better positioned to attract tenants.

Investors watching the sector should also keep an eye on interest rates, as they directly affect REIT borrowing costs and the appeal of income-paying stocks. A rate cut could provide a tailwind for the entire group, while a prolonged period of high rates could keep pressure on valuations.

Bottom line

UBS's price target increase and BXP's raised guidance are positive signals for the company's future, but they come with a caveat: this year's results will be tempered by the accelerated asset sales. For investors, the story is about patience—BXP is betting that its leasing momentum will pay off in the coming years, even if the near-term picture is less rosy.

As always, it's wise to consider how any single stock fits into your broader portfolio and risk tolerance. Analyst actions like this are useful data points, but they should be weighed alongside your own research and financial goals.

More from this story

Next article · Don't miss

Chip and pharma projects could lift US factory construction above $200B

UBS expects US factory construction to rebound, led by new chip and pharma projects. Manufacturing-related building could top $200 billion by end of next year after a recent slowdown.

Read the story →
Chip and pharma projects could lift US factory construction above $200B